Tuesday, April 14, 2026 – Wednesday, April 15 - Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to improve organ function and does so independently of weight loss. The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease.

Tuesday, April 14, 2026 – Wednesday, April 15 - With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.

Tuesday, April 14, 2026 – Tuesday, April 14 - Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years. Continue reading...

Monday, April 13, 2026 – Tuesday, April 14 - — Your genetics might play a role in how well cutting-edge weight loss drugs like Ozempic and Zepbound will work for you, a new study says.Specific genetic traits can affect both weight loss and side effects for people taking...

Monday, April 13, 2026 – Tuesday, April 14 - Amazon will offer the new GLP-1 pill, Foundayo, via kiosks and same-day delivery. Image credit: Michael Nagle/Bloomberg via Getty Images

Eli Lilly has announced the availability of the new GLP-1 pill, Foundayo, through Amazon One Medical kiosks. .

Monday, April 13, 2026 – Monday, April 13 - A newly discovered molecule could reshape the future of weight loss treatments by mimicking the powerful appetite-suppressing effects of drugs like Ozempic — but without many of the unpleasant side effects. Identified using artificial intelligence, this tiny peptide, called BRP, appears to act directly on the brain’s appetite-control center, helping animals eat less and lose fat without nausea or muscle loss.

Sunday, April 12, 2026 – Monday, April 13 - A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.

Saturday, April 11, 2026 – Saturday, April 11 - More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

Friday, April 10, 2026 – Saturday, April 11 - (MedPage Today) -- GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of...

Friday, April 10, 2026 – Saturday, April 11 - Here’s everything we know so far.